Recent Insider Activity: C R Bard (BCR)

C R Bard Inc (NYSE:BCR) insider has recently participated in insider trading activity. Chairman and CEO, RING TIMOTHY M sold 2,453 shares for $ 460,226 via one transaction Feb 17. Another notable insider trading was done by WEILAND JOHN H on Feb 17, who is the President and COO. The insider sold 1,618 shares at an average price of $187.45. Moreover, an insider selling of 661 shares was carried out by DeFord John A, Sr. VP Sci Tech and Clin Afrs, on Feb 17. Following the transaction, the insider now owns 123,898 shares in total. Group President Collins Timothy P sold 974 shares for $ 182,606 through one transaction Feb 17. Following this sale, this insider’s stake in the company comprises 29,276 shares, priced at $ 5484273.08 as of Thursday.

The stock has experienced a total of 89 insider trades in the past three months. These trades include 64 sell activities and 25 buy trades. Furthermore, over the past 12 months, the stock was traded 123 times by insiders. In 98 of these trades, the insider was a seller while an employee of the company was the buyer in just 25 instances.

On January 28, 2016, C R Bard Inc (BCR) reported 2015 fourth quarter financial results. Fourth quarter 2015 net sales were $870.8 million, compared to fourth quarter 2014 net sales of $867.2 million on an as-reported basis. Excluding the impact of foreign exchange, fourth quarter 2015 net sales increased 3 percent over the prior-year period.

For the fourth quarter 2015, net sales in the U.S. were $605.8 million and net sales outside the U.S. were $265.0 million, an increase of 2 percent and a decrease of 4 percent, respectively, over the prior-year period. Excluding the impact of foreign exchange, fourth quarter 2015 net sales outside the U.S. increased 5 percent over the prior-year period.

Net sales for the full year 2015 were $3,416.0 million, an increase of 3 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, full year 2015 net sales increased 6 percent over the prior-year period.

1. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and temporary pacing electrode catheters for the treatment of peripheral vascular and end-stage renal diseases, and heart arrhythmias.